- Home
- HTCO vs AVIR Comparison
HTCO vs AVIR Comparison
Compare HTCO & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTCO
- AVIR
- Stock Information
- Founded
- HTCO N/A
- AVIR 2012
- Country
- HTCO Singapore
- AVIR United States
- Employees
- HTCO N/A
- AVIR N/A
- Industry
- HTCO
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- HTCO
- AVIR Health Care
- Exchange
- HTCO NYSE
- AVIR Nasdaq
- Market Cap
- HTCO 210.6M
- AVIR 247.5M
- IPO Year
- HTCO N/A
- AVIR 2020
- Fundamental
- Price
- HTCO $2.30
- AVIR $3.29
- Analyst Decision
- HTCO
- AVIR Hold
- Analyst Count
- HTCO 0
- AVIR 1
- Target Price
- HTCO N/A
- AVIR $6.88
- AVG Volume (30 Days)
- HTCO 151.6K
- AVIR 491.5K
- Earning Date
- HTCO 02-15-2025
- AVIR 11-07-2024
- Dividend Yield
- HTCO N/A
- AVIR N/A
- EPS Growth
- HTCO N/A
- AVIR N/A
- EPS
- HTCO N/A
- AVIR N/A
- Revenue
- HTCO $80,567,672.00
- AVIR N/A
- Revenue This Year
- HTCO N/A
- AVIR N/A
- Revenue Next Year
- HTCO N/A
- AVIR N/A
- P/E Ratio
- HTCO N/A
- AVIR N/A
- Revenue Growth
- HTCO N/A
- AVIR N/A
- 52 Week Low
- HTCO $0.21
- AVIR $2.75
- 52 Week High
- HTCO $2.78
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- HTCO N/A
- AVIR 49.07
- Support Level
- HTCO N/A
- AVIR $3.10
- Resistance Level
- HTCO N/A
- AVIR $3.27
- Average True Range (ATR)
- HTCO 0.00
- AVIR 0.16
- MACD
- HTCO 0.00
- AVIR 0.02
- Stochastic Oscillator
- HTCO 0.00
- AVIR 55.28
About HTCO CARAVELLE INTERNATIONAL GROUP
Caravelle International Group is an international operator of ocean transportation services. It is engaged in the seaborne transportation service under voyage contracts as well as vessel service for and on behalf of ship owners. The company has two operating segments namely, ocean transport and Heating business. The company derives the majority of its revenue from the Ocean transportation business. The company derives freight revenue from voyage contracts and provides vessel service.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).